GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (NAS:APDN) » Definitions » Cash Flow from Financing

Applied DNA Sciences (Applied DNA Sciences) Cash Flow from Financing : $2.98 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Applied DNA Sciences Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Applied DNA Sciences received $2.94 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.08 Mil on other financial activities. In all, Applied DNA Sciences earned $3.02 Mil on financial activities for the three months ended in Mar. 2024.


Applied DNA Sciences Cash Flow from Financing Historical Data

The historical data trend for Applied DNA Sciences's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied DNA Sciences Cash Flow from Financing Chart

Applied DNA Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 19.44 14.71 18.13 -

Applied DNA Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.04 3.02

Applied DNA Sciences Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Applied DNA Sciences's Cash from Financing for the fiscal year that ended in Sep. 2023 is calculated as:

Applied DNA Sciences's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied DNA Sciences  (NAS:APDN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Applied DNA Sciences's issuance of stock for the three months ended in Mar. 2024 was $2.94 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Applied DNA Sciences's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Applied DNA Sciences's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Applied DNA Sciences received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Applied DNA Sciences's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Applied DNA Sciences paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Applied DNA Sciences's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Applied DNA Sciences received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Applied DNA Sciences's other financing for the three months ended in Mar. 2024 was $0.08 Mil. Applied DNA Sciences received $0.08 Mil on other financial activities.


Applied DNA Sciences Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied DNA Sciences (Applied DNA Sciences) Business Description

Traded in Other Exchanges
Address
50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Executives
Clay Shorrock officer: Chief Legal Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Scott L Anchin director 16990 GOLDENTOP ROAD, SUITE A, SAN DIEGO CA 92127
William W Montgomery 10 percent owner 34211 SEAVEY LOOP RD., EUGENE OR 97405
Judith Murrah officer: Chief Information Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Beth Jantzen officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov A Shamash director
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
John Iii Bitzer director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Joseph D. Ceccoli director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Elizabeth M. Ferguson director 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Charles S. Ryan director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
James A Hayward director, officer: Chief Executive Officer C/O 25 HEALTH SCIENCES DRIVE, SUITE 113, NEW YORK NY 11790
Karol Gray officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Ming-hwa Benjamin Liang officer: Strategic Tech. Dev. Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov Shamash director 100 ENGINEERING, STATE UNIVERSITY OF NY, STONE BROOK NY 117942200

Applied DNA Sciences (Applied DNA Sciences) Headlines

From GuruFocus